(IN BRIEF) Merck has entered into a definitive agreement to acquire SpringWorks Therapeutics for approximately $3.9 billion. This acquisition will significantly enhance Merck’s rare tumor portfolio, adding first-in-class therapies for desmoid tumors and NF1-PN. The deal aligns with Merck’s strategy … Read the full press release →
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged acquisition, biopharmaceuticals, cancer treatments, desmoid tumors, Healthcare Innovation, M&A, Merck, NF1-PN, partnership, pharmaceutical acquisition, rare tumors, SpringWorks Therapeutics, U.S. healthcare